These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 15607431)
1. Advanced glycation end-product cross-link breakers. A novel therapeutic pathway for cardiovascular disease. Hollenberg NK Am J Hypertens; 2004 Dec; 17(12 Pt 2):21S-22S. PubMed ID: 15607431 [No Abstract] [Full Text] [Related]
2. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Bakris GL; Bank AJ; Kass DA; Neutel JM; Preston RA; Oparil S Am J Hypertens; 2004 Dec; 17(12 Pt 2):23S-30S. PubMed ID: 15607432 [TBL] [Abstract][Full Text] [Related]
3. Cross-link breakers as a new therapeutic approach to cardiovascular disease. Susic D Biochem Soc Trans; 2007 Nov; 35(Pt 5):853-6. PubMed ID: 17956231 [TBL] [Abstract][Full Text] [Related]
4. Characteristics, formation, and pathophysiology of glucosepane: a major protein cross-link. Sjöberg JS; Bulterijs S Rejuvenation Res; 2009 Apr; 12(2):137-48. PubMed ID: 19415980 [TBL] [Abstract][Full Text] [Related]
5. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797 [TBL] [Abstract][Full Text] [Related]
6. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Meerwaldt R; Zeebregts CJ; Navis G; Hillebrands JL; Lefrandt JD; Smit AJ Am J Kidney Dis; 2009 Jan; 53(1):138-50. PubMed ID: 19036487 [TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention. Yamagishi S; Nakamura K; Takeuchi M; Imaizumi T Int J Clin Pharmacol Res; 2004; 24(4):129-34. PubMed ID: 15754918 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of green tea extract on advanced glycation and cross-linking of collagen in the aorta of streptozotocin diabetic rats. Babu PV; Sabitha KE; Shyamaladevi CS Clin Exp Pharmacol Physiol; 2006 Apr; 33(4):351-7. PubMed ID: 16620300 [TBL] [Abstract][Full Text] [Related]
9. Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease. Yamagishi S; Nakamura K; Matsui T; Ueda S; Noda Y; Imaizumi T Cardiovasc Ther; 2008; 26(1):50-8. PubMed ID: 18466420 [TBL] [Abstract][Full Text] [Related]
10. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Izuhara Y; Sada T; Yanagisawa H; Koike H; Ohtomo S; Dan T; Ito S; Nangaku M; van Ypersele de Strihou C; Miyata T Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1767-73. PubMed ID: 18658044 [TBL] [Abstract][Full Text] [Related]
11. The blood pressure measurement--revisited. Safar ME; Smulyan H Am Heart J; 2006 Sep; 152(3):417-9. PubMed ID: 16923406 [No Abstract] [Full Text] [Related]
12. Immunohistochemical demonstration of advanced glycation end products and the effects of advanced glycation end products in ossified ligament tissues in vitro. Yokosuka K; Park JS; Jimbo K; Yoshida T; Yamada K; Sato K; Takeuchi M; Yamagishi S; Nagata K Spine (Phila Pa 1976); 2007 May; 32(11):E337-9. PubMed ID: 17495767 [TBL] [Abstract][Full Text] [Related]
13. A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Izuhara Y; Nangaku M; Takizawa S; Takahashi S; Shao J; Oishi H; Kobayashi H; van Ypersele de Strihou C; Miyata T Nephrol Dial Transplant; 2008 Feb; 23(2):497-509. PubMed ID: 17928329 [TBL] [Abstract][Full Text] [Related]
14. A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches? Sourris KC; Harcourt BE; Forbes JM Am J Nephrol; 2009; 30(4):323-35. PubMed ID: 19556753 [TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end-products prepared in solution under high pressure contain epitopes distinct from those formed in the dry reaction at high temperature. Staniszewska M; Jarosz J; Jon M; Gamian A Arch Immunol Ther Exp (Warsz); 2005; 53(1):71-8. PubMed ID: 15761378 [TBL] [Abstract][Full Text] [Related]
16. Mass spectrometry to detect the site specificity of advanced glycation/lipoxidation end-product formation on protein: some challenges and solutions. Ames JM Biochem Soc Trans; 2008 Oct; 36(Pt 5):1051-4. PubMed ID: 18793187 [TBL] [Abstract][Full Text] [Related]
17. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders. Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular disease in dialysis patients: do some antihypertensive drugs have specific antioxidant effects or is it just blood pressure reduction? Does antioxidant treatment reduce the risk for cardiovascular disease? Aslam S Curr Opin Nephrol Hypertens; 2008 Jan; 17(1):99-105. PubMed ID: 18090678 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of naphthoic acid derivatives as fluorescent probes to screen advanced glycation end-products breakers. Séro L; Calard F; Sanguinet L; Levillain E; Richomme P; Séraphin D; Derbré S Bioorg Med Chem Lett; 2012 Nov; 22(21):6716-20. PubMed ID: 23010265 [TBL] [Abstract][Full Text] [Related]